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Abstract 1 
Protein homeostasis, or proteostasis, is the process of maintaining the conformational and 2 
functional integrity of the proteome. Proteostasis is preserved in the face of stress by a complex 3 
network of cellular machinery, including the small heat shock molecular chaperone proteins (sHsps), 4 
which act to inhibit the aggregation and deposition of misfolded protein intermediates. Despite this, 5 
the pathogenesis of several neurodegenerative diseases has been inextricably linked with the 6 
amyloid fibrillar aggregation and deposition of α-synuclein (α-syn). The sHsps are potent inhibitors of 7 
α-syn aggregation in vitro. However, the limited availability of a robust, cell-based model of α-syn 8 
aggregation has, thus far, restricted evaluation of sHsp efficacy in the cellular context. As such, this 9 
work sought to establish a robust model of intracellular α-syn aggregation using Neuro-2a cells. 10 
Aggregation of α-syn was found to be sensitive to inhibition of autophagy and the proteasome, 11 
resulting in a significant increase in the proportion of cells containing α-syn inclusions. This model 12 
was then used to evaluate the capacity of the sHsps, αB-c and Hsp27, to prevent α-syn aggregation 13 
in cells. To do so, we used bicistronic expression plasmids to express the sHsps. Unlike traditional 14 
fluorescent fusion constructs, these bicistronic expression plasmids enable only individual 15 
transfected cells expressing the sHsps (via expression of the fluorescent reporter) to be analysed, 16 
but without the need to tag the sHsp, which can affect its oligomeric structure and chaperone 17 
activity. Overexpression of both αB-c and Hsp27 significantly reduced the intracellular aggregation of 18 
α-syn. Thus, these findings suggest that overexpressing or boosting the activity of sHsps may be a 19 
way of preventing amyloid fibrillar aggregation of α-syn in the context of neurodegenerative disease.  20 
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Introduction 21 
Parkinson’s disease (PD) is the second most prevalent form of age-related neurodegenerative 22 
disorder, with its world-wide incidence projected to reach at least 8.7 million individuals over 50 23 
years of age by 2030 (de Lau and Breteler 2006, Dorsey et al. 2007, Massano and Bhatia 2012). The 24 
pathogenesis of PD, and other neurodegenerative diseases, has been inextricably linked with the 25 
amyloid fibrillar aggregation and deposition of α-synuclein (α-syn). The initiation of aggregation in 26 
this context results from dysfunction in the cellular defence mechanisms that would otherwise 27 
maintain protein homeostasis, or proteostasis. Proteostasis refers to the preservation of proteins in 28 
their correct location, concentration and conformation, enabling them to fulfil their biological 29 
function (Balch et al. 2008). As such, proteostasis relies on a number of integrated pathways, 30 
including those involved in transcription and translation, protein folding, trafficking and 31 
compartmentalisation, and finally degradation (Yerbury et al. 2005). Key components of this 32 
proteostasis network are the molecular chaperones, which assist proteins in acquiring and 33 
maintaining their native conformation.  34 
The small heat shock proteins (sHsps) are a family of molecular chaperones that are among the first 35 
and most up-regulated in response to cellular stress. At present, there are ten recognised 36 
mammalian sHsps (HSPB1 – HSPB10); the most well characterised are Hsp27 (HSPB1) and αB-37 
crystallin (αB-c; HSPB5) (Kampinga et al. 2009, Carra et al. 2013). The sHsp chaperones are defined 38 
by the presence of a conserved, central α-crystallin domain of approximately 90 residues, flanked by 39 
variable N- and C-terminal regions (de Jong et al. 1993). In addition, while the sHsps are 40 
characterised by a relatively small monomeric mass (typically 12 – 43 kDa), they are known to form 41 
oligomeric species which, in the case of Hsp27 and αB-c, are polydisperse and undergo dynamic 42 
subunit exchange (Bova et al. 1997, Bova et al. 2000, Van Montfort et al. 2002, Lelj-Garolla and 43 
Mauk 2006, Ahmad et al. 2008, Benesch et al. 2008, Jehle et al. 2010, Jehle et al. 2011). The dynamic 44 
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exchange of subunits between oligomers is thought to be crucial for the chaperone action of these 45 
sHsps. 46 
Both Hsp27 and αB-c have been shown to be potent inhibitors of α-syn aggregation using in vitro, 47 
solution-based assays (Bruinsma et al. 2011, Cox et al. 2016). However, it remains to be established 48 
whether these sHsps can prevent the aggregation of α-syn in cells (Cox et al. 2014). Cell-based 49 
models of α-syn aggregation have provided some evidence that sHsps can inhibit α-syn aggregation 50 
and/or the toxicity associated with this process (Klucken et al. 2004, Zourlidou et al. 2004, Outeiro et 51 
al. 2006). However, an issue with some of these cell-based models of a-syn aggregation, which has 52 
hampered their use in quantitative studies, is that only a small proportion of the cells in culture 53 
develop inclusions (typically less than 5% in studies where this is has been quantified) (McLean et al. 54 
2001, Klucken et al. 2004, Zourlidou et al. 2004, Outeiro et al. 2006). This severely limits the types of 55 
biochemical analyses that can be undertaken with these models. Therefore, in this work we sought 56 
to develop a robust, reliable and quantifiable cell-based model of α-syn aggregation in order to 57 
examine whether the sHsps Hsp27 and αB-c can inhibit α-syn aggregation in cells.  58 
In developing a model to study sHsp chaperone function in cells we have also considered the impact 59 
of attaching a (bulky) fluorescent tag to sHsps.  The formation of dynamic oligomers is a 60 
characteristic feature of Hsp27 and αB-c (Bova et al. 2000, Van Montfort et al. 2002). Recent work 61 
has demonstrated that the addition of a fluorescent protein tag to the N- or C-terminus of αB-c or 62 
Hsp27 significantly impacts the ability of these sHsps to form oligomeric assemblies and chaperone 63 
activity, compared to the non-labelled protein (Datskevich et al. 2012a, Datskevich et al. 2012b, 64 
Datskevich and Gusev 2014). Unfortunately, the expression of untagged sHsps in cells does not 65 
readily allow differences in transfection efficiency and expression levels to be taken into account 66 
when comparing between individual cells and samples in an experiment, which can confound 67 
analyses. We therefore sought an alternate method to evaluate the chaperone activity of sHsps in 68 
cells that did not involve tagging them with a fluorescent protein, but does enable differences in 69 
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transfection efficiencies and protein expression to be accounted for in downstream analyses. 70 
Bicistronic expression constructs enable the simultaneous expression of a gene of interest (in this 71 
case a sHsp) and a fluorescent (reporter) protein (in this case EGFP) from the one mRNA. Moreover, 72 
the mRNA contains an internal ribosome entry site (IRES) such that the expression of the sHsp of 73 
interest and fluorescent protein is correlated. Thus, the levels of the fluorescent protein can act as a 74 
reporter of the expression of the gene of interest. Use of IRES constructs therefore allows 75 
transfected cells to be detected, and the relative levels of the gene of interest (in this case the sHsp) 76 
to be quantified (based on the expression levels of the fluorescent reporter), without the need to 77 
add a fluorescent tag directly to the protein. 78 
In this work, we describe the development of a robust and reliable cell-based model of α-syn 79 
aggregation. This model was then employed to evaluate the ability of the sHsps Hsp27 and αB-c to 80 
prevent a-syn aggregation into inclusions in cells. As the addition of a fluorescent tag potentially 81 
impacts the function of sHsps in cells (Datskevich et al. 2012a, Datskevich et al. 2012b, Datskevich 82 
and Gusev 2014), bicistronic IRES vectors were used to express Hsp27 or αB-c. Our findings 83 
demonstrate that these sHsps are effective in inhibiting the aggregation and deposition of α-syn into 84 
inclusions in cells.  85 
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Materials and Methods 86 
Materials 87 
All materials used in this work were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Amresco 88 
(Solon, OH, U.S.A.) unless otherwise indicated. The pET24a(+) bacterial expression vector, containing 89 
the human SNCA (α-syn) gene, was used for expression of recombinant α-syn in chemically 90 
competent BL21 (DE3) E. coli. Recombinant α-syn was expressed, purified and quantified as 91 
described previously (Cox et al. 2016). Seed fibrils were produced from monomeric α-syn as 92 
described previously (Brown et al. 2016), and were used to produce mature fibrils. Briefly, 93 
recombinant monomeric α-syn (100 µM) was incubated at 37oC in 50 mM phosphate buffer (pH 7.4) 94 
in the presence of 1 µM preformed seed fibrils for 48 h.  95 
The pEGFP-N3 mammalian expression vectors, containing the human SNCA (α-syn) gene with or 96 
without the disease-related mutation (A53T), were a gift from Dr. Dean Poutney (Griffith University, 97 
Australia), and were used to induce cellular expression of α-syn variants C-terminally tagged with 98 
EGFP. The pCMV6-AC-GFP mammalian expression vector, containing M337V TDP-43 cDNA C-99 
terminally tagged with TurboGFP (tGFP), was a gift from Dr. Daniel Whiten (University of 100 
Wollongong, Australia). The bicistronic pIRES2-EGFP vector was a kind gift from Dr Lezanne Ooi 101 
(University of Wollongong, Australia). Constructs containing αB-c, Hsp27, or the non-chaperone 102 
control protein, an ‘invisible’ isoform of EGFP, EGFPinv (i.e. a non-fluorescent Y66L mutant form of 103 
EGFP (Olshina et al. 2010, Ramdzan et al. 2012)), were generated by amplifying genes encoding the 104 
genes (with flanking restriction sites) from existing plasmid constructs for sub-cloning upstream of 105 
the IRES site of the pIRES2 plasmids; αB-crystallin (CRYAB; GenBank NM_001885) with NheI/SalI, 106 
HSP27 (HSPB1; GenBank BT019888.1) with BglII/SalI, and EGFPinv with flanking BglII/EcoRI sites. 107 
Sequences of all constructs were verified prior to use.  108 
Mouse neuroblastoma cells (Neuro-2a; N2a) and human embryonic kidney (HEK293) cells were 109 
obtained from the American Type Culture Collection (Manassas, VA, U.S.A.). Both cell lines were 110 
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routinely tested for mycoplasma contamination every 6 months, and the identity of the human-111 
derived cell line was verified via short tandem repeat (STR) profiling (Garvan Institute of Medical 112 
Research, Sydney, Australia). For immunolabelling of α-syn, mouse monoclonal anti-α-syn antibody 113 
(clone Syn211) and a peroxidase conjugated anti-mouse IgG secondary antibody were obtained from 114 
Sigma-Aldrich (St. Louis, USA). For immunolabelling of sHsps, rabbit polyclonal anti-αBc (ab13497) 115 
and anti-Hsp27 (ab5579) antibodies were acquired from Abcam (Cambridge, UK). Goat anti-mouse 116 
and anti-rabbit secondary antibodies conjugated to DyLight650 (ab96874 and ab96902 respectively), 117 
mouse (ab37355) and rabbit (ab171870) IgG controls were also purchased from Abcam (Cambridge, 118 
UK).  119 
Cloning of α-synA53T* expression construct 120 
The cloning strategy was designed according to findings published by McLean and colleagues (2001) 121 
(McLean et al. 2001), in which an aggregation-prone cleavage product of α-syn was identified within 122 
cells initially transfected to express α-syn with a C-terminal EGFP tag (i.e. α-syn-EGFP). Specifically, 123 
this product was approximately 27 kDa, and corresponded to a cleaved form of α-syn-EGFP in which 124 
the last 155 residues from the C-terminal region of EGFP were removed. This resulted in α-syn fused 125 
to a non-fluorescent fragment of EGFP. The region corresponding to α-synA53T and the first 85 126 
residues of EGFP (i.e. lacking the last 155 residues, designated α-synA53T*) was amplified from the 127 
original α-synA53T-EGFP construct by PCR using MyTaq DNA polymerase, the CMV-F primer (5’ – 128 
CGCAAATGGGCGGTAGGCGTG – 3’) and a custom designed primer (5’ – 129 
CTTGCGGCCGCCTAGAAGAAGTCGTGCTGC – 3’) containing the NotI  restriction site (bold text). PCR 130 
was performed using a Mastercycler ProS (Eppendorf) and consisted of 35 cycles, with each cycle 131 
consisting of denaturation at 95°C for 15 s, annealing at 55°C for 15 s, and extension at 72°C for 10 s. 132 
The amplified product was gel purified, digested using the restriction enzymes Acc65I and NotI, and 133 
ligated back into the pEGFP-N3 vector.  A clone positive for the α-synA53T* insert was selected and 134 
plasmid DNA extracted and sequenced.  135 
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Culture and transfection of mammalian cell lines 136 
Mammalian cell lines (N2a and HEK293) were chosen due to the ease with which they can be 137 
cultured, transfected and imaged. In addition, N2a cells represent a well-established neuronal model 138 
used for characterising aggregation (Krishnan et al. 2006, Ojha et al. 2011, Ormsby et al. 2013, Chai 139 
et al. 2016). Cells were cultured in Dulbecco's Modified Eagle's Medium/Ham's Nutrient Mixture F-140 
12 (DMEM/F12; ThermoFischer Scientific, Waltham, USA) supplemented with 10% (v/v) foetal 141 
bovine serum (FBS; Bovagen Biologicals, East Keilor, Australia) and 2.5 mM L-glutamine 142 
(ThermoFischer Scientific, Waltham, USA). All media was sterile filtered and warmed to 37oC for use. 143 
All tissue culture was performed within a laminar flow biosafety cabinet, and cells were incubated in 144 
a Heracell 150i CO2 incubator (ThermoFischer Scientific, Waltham, USA) under 5% CO2/95% air at 145 
37oC.  146 
Cells were passaged when at 80% confluency or after a period of 72 h, and reseeded into fresh 147 
CELLSTAR flasks or culture plates (both from Greiner Bio-one, Frickenhausen, Germany) where 148 
required. For plating purposes, cells were seeded at 100 000 cells/mL in 6-well, 12-well or 24-well 149 
plates (Greiner Bio-One, Frickenhausen, Germany), or 8-well chamber slides (Ibidi, Martinsried, 150 
Germany) and grown overnight. Cells were then transfected using Lipofectamine® LTX (Invitrogen, 151 
Waltham, U.S.A.) according to the manufacturer’s instructions. Briefly, DNA:liposome complexes 152 
were generated by incubation of 1 μg of plasmid DNA in serum free DMEM/F12 with 3 µL of 153 
Lipofectamine® LTX and  1 µL PLUS™ reagent per ~3.5 cm2 of cells to be transfected, at room 154 
temperature for 30 min. In the case of dual transfections, DNA:liposome complexes for each plasmid 155 
were prepared separately then combined after the 30 min incubation period to allow mixing. In this 156 
way, each plasmid is incorporated into separate liposomes, which can then be independently taken 157 
up by cells. Dual transfections were completed at a 1:4 (IRES:α-syn) (w/w) ratio of DNA. DNA 158 
complexes were then applied to cells in fresh culture medium and incubated for 48 h at 37°C under 159 
5% CO2/95% air. 160 
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Where necessary, cells were treated with various inhibitors of proteostasis pathway components to 161 
induce cellular stress. Treatments included a proteasome inhibitor (MG132; 10 µM), an autophagy 162 
inhibitor (3-methyladenine (3-MA); 10 mM), an inducer of ER stress (thapsigargin; 3 µM), or an 163 
inducer of oxidative stress (FeCl2; 10 mM), all of which were solubilised in DMSO as 1000-times 164 
stocks and subsequently diluted into serum free DMEM/F12 for addition to cultured cells. The 165 
inhibitor concentrations were selected according to previously reported and commonly used 166 
concentrations (Ostrerova-Golts et al. 2000, Fioriti et al. 2005, Földi et al. 2013, Gui et al. 2014, Guo 167 
et al. 2016). Mock treated cells were exposed to the appropriate concentration of DMSO in serum 168 
free DMEM/F12. 169 
Immunolabelling of α-syn and sHsps 170 
Intracellular α-syn was routinely detected via immunocytochemistry. Cells were seeded at 100 000 171 
cells/mL onto sterilised 19 mm glass coverslips (ProSciTech, Thuringowa, Australia) or in 8-well 172 
chamber slides (Ibidi, Martinsried, Germany) and transfected as described above. After 48 h, or 173 
following treatment for the times indicated, culture medium was removed from the cells and the 174 
cells washed twice with PBS. Cells were fixed via incubation with 4% (w/v) paraformaldehyde (PFA, 175 
pH 7.4) for 20 min at room temperature and washed twice with PBS. Cells were then permeabilised 176 
using 0.5% (v/v) Triton X-100 in PBS for 20 min at room temperature, before being washed twice 177 
with 1% (w/v) BSA in PBS. Cells were then blocked using 5% (w/v) BSA in PBS, and washed twice in 178 
1% (w/v) BSA in PBS-Tween 20 (PBS-T; PBS containing 0.05% (v/v) Tween-20). Immunolabelling of α-179 
syn was achieved using the mouse monoclonal anti-α-syn antibody diluted 1:500 with 1% (w/v) BSA 180 
in PBS-T. Alternatively, sHsps were detected using rabbit polyclonal anti-αBc or anti-Hsp27 181 
antibodies diluted 1:500 with 1% (w/v) BSA in PBS-T. Cells were incubated at 37oC for 1 h in a 182 
humidity chamber, before being washed three times with 1% (w/v) BSA in PBS-T. The appropriate 183 
fluorophore-conjugated secondary antibody was diluted 1:500 with 1% (w/v) BSA in PBS-T, and 184 
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applied to the cells. Following incubation at 37oC for 1 h in a humidity chamber, cells were then 185 
washed four times with 1% (w/v) BSA in PBS-T. 186 
Confocal microscopy and image analysis 187 
Coverslips with cells containing fluorescent and/or immunolabelled proteins were mounted onto 26 188 
× 76 mm glass slides (ThermoFischer Scientific, Waltham, USA) using Citifluor™ Anti-Fadent 189 
Mounting Solutions (9:1 (v/v) ratio of Citifluor™ CFPVOH: Citifluor™ AF100 anti-fadent; ProSciTech, 190 
Thuringowa, Australia) and allowed to set at room temperature for 1 h prior to imaging. 191 
Alternatively, cells in chamber slides were overlayed with PBS containing 10% (v/v) Citifluor™ AF100 192 
anti-fadent (ProSciTech, Thuringowa, Australia) and imaged immediately. Cells were observed using 193 
a Leica TCS SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany). Fluorescent 194 
conjugates were excited at 488 nm, 561 nm, or 633 nm by argon, DPS 561, and HeNe lasers, 195 
respectively. Fluorescent emissions were acquired by sequential scanning using the Leica Application 196 
Suite –Advanced Fluorescence (LAS-AF) software v3 (Leica Microsystems, Wetzlar, Germany). Either 197 
photomultiplier tube (PMT) or hybrid (HyD) detectors were selected and custom filter windows set 198 
according to the intensity and emission spectrum of the fluorophore of interest. Gains and filter 199 
windows were set according to the untransfected and isotype (mouse or rabbit IgG) stained controls 200 
using the overflow colour map, such that samples were below the saturation point, background or 201 
non-specific fluorescence was not visible and bleed through was eliminated. 202 
Images collected via confocal microscopy were processed manually with ImageJ (National Institutes 203 
of Health, Bethesda, U.S.A.) using custom written macro scripts (Supplementary Information, Figure 204 
S1). These methods were developed to enable non-subjective quantification of the number of cells 205 
with aggregates between samples. Briefly, cell boundaries of individual cells were defined using the 206 
brightfield image, and the transfected cells determined automatically via thresholding of the 207 
fluorescent image. Cells containing inclusions (visually defined as fluorescent puncta) were manually 208 
selected according to the fluorescent image. The percentage of transfected cells (or co-transfected 209 
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cells in experiments involving the IRES constructs) with and without inclusions for each treatment 210 
was calculated by the custom written Python script. This was completed with at least 50 cells per 211 
treatment over four biological repeats. All statistical analyses (unless otherwise stated) were 212 
performed using GraphPad Prism v 5 (GraphPad Software Inc., San Diego, USA) software. 213 
Filter-trap assay 214 
In order to confirm the presence of insoluble α-syn inclusions in cells, a filter-trap assay was 215 
performed. Cells were transfected, treated with inhibitors where appropriate and harvested. Cell 216 
pellets were washed twice in PBS, and then resuspended in lysis buffer (PBS containing 0.5% (v/v) 217 
Triton-X 100, pH 7.4, supplemented with 0.5% (v/v) Halt™ Protease and Phosphatase Inhibitor 218 
Cocktail). The total protein concentration for each sample was then determined using a Pierce BCA 219 
assay (ThermoFischer Scientific, Waltham, USA) according to the manufacturer’s instructions. 220 
Samples were diluted to 1 mg/mL using lysis buffer and kept on ice until use. In addition, samples 221 
containing known concentrations of recombinant monomeric or fibrillar α-syn were similarly 222 
prepared in PBS or spiked into lysis buffer and kept on ice.  223 
In order to determine the concentration of α-syn in samples produced following transfection with 224 
the α-synA53T* construct, a dot blot was first performed. Samples were spotted onto nitrocellulose 225 
membrane, and left to dry at room temperature for 1 h. The membrane was then blocked at room 226 
temperature for 1 h in Tris-buffered saline (TBS; 50 mM Tris and 150 mM NaCl, pH 7.5) containing 227 
5% (w/v) skim milk powder. Blots were then incubated overnight at 4oC in TBS-Tween-20 (TBST; TBS 228 
containing 0.05% (v/v) Tween-20) containing 5% (w/v) skim milk powder and the mouse monoclonal 229 
anti-α-syn antibody (diluted 1:5000). Blots were washed four times in TBST for 10 min with constant 230 
agitation, then incubated at room temperature for 1 h in TBST containing 5% (w/v) skim milk powder 231 
and the peroxidase-conjugated anti-mouse secondary antibody (diluted 1:5000). Blots were washed 232 
as above, and then labelled α-syn was detected using SuperSignal West Pico Chemiluminescent 233 
Substrate or SuperSignal West Dura Extended Duration Chemiluminescent Substrate according to 234 
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the manufacturer’s instructions (ThermoFischer Scientific, Waltham, USA). The membrane was 235 
exposed to Amersham Hyperfilm ECL chemiluminescence film (GE Healthcare, Uppsala, Sweden), or 236 
directly imaged using a Gel Logic 2200 Pro Imaging System (Carestream Health, Rochester, NY, USA) 237 
or Amersham Imager 600 (GE Healthcare, Uppsala, Sweden). 238 
The intensity of spots of interest were analysed using the gel quantification function in ImageJ, and a 239 
standard curve of concentration of recombinant α-syn versus spot intensity was generated 240 
(Supplementary Information, Figure S2). The concentration of α-syn in the transfected cell extracts 241 
was then determined via interpolation from the standard curve and was found to be less than 1 µM.  242 
The Bio-Dot microfiltration apparatus (Bio-Rad, Hercules, CA) was prepared according to the 243 
manufacturer’s instructions. Briefly, 0.22 µm cellulose acetate membrane (Whatman, Maidstone, 244 
UK) and three sheets of Bio-DOT SF filter paper (Bio-Rad, Hercules, CA) were equilibrated in PBS 245 
containing 1% (w/v) SDS (pH 7.4) for 10 min at room temperature. The Bio-Dot apparatus was then 246 
assembled containing the membrane and filter paper and tightened under vacuum. Each slot for use 247 
was rehydrated with 200 µL PBS, which was then filtered under vacuum immediately prior to the 248 
addition of 200 µg of the prepared cell lysate or appropriate control samples. Any unused slots were 249 
sealed with clear sealing film, and samples filtered under gentle vacuum. Once all samples had been 250 
filtered, 200 µL of PBS was added to the sample well and filtered under gentle vacuum. The 251 
membrane was then removed and blocked in 5% (w/v) skim milk powder in TBS, before being 252 
analysed via the immunoblotting technique described above.  253 
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Results 254 
Fluorescently-tagged α-syn isoforms do not readily aggregate in cells 255 
Transfection with fluorescently tagged aggregation-prone proteins is a common method for 256 
investigating cellular aggregation, including that of α-syn (McLean et al. 2001, Outeiro et al. 2006). 257 
As such, N2a cells were transfected with constructs encoding for α-synWT-EGFP, α-synA53T-EGFP, 258 
EGFP (negative control) or TDP-43-tGFP (positive control). Given the importance of the proteostasis 259 
network in modulating cellular aggregation, targeting pathways of this network is a common method 260 
of inducing the aggregation of proteins into inclusions (Outeiro et al. 2006, Bertoncini et al. 2007, 261 
Wan and Chung 2012). As such, transfected cells were incubated in the absence or presence of 262 
MG132 (10 µM, proteasome inhibitor), thapsigargin (3 µM, inducer of ER stress) or FeCl2 (10 mM, 263 
inducer of oxidative stress). Cells were then imaged via confocal microscopy (Figure 1A), and EGFP-264 
positive cells containing diffuse fluorescence (left box, 1) or fluorescent puncta (right box, 2) were 265 
enumerated. The percentage of EGFP-positive cells containing inclusions was then compared with 266 
the untreated, EGFP-expressing negative control cells (Figure 1B). As expected, there was a 267 
significantly higher (p<0.001) proportion of cells expressing TDP-43-tGFP with inclusions (41.5 ± 268 
7.20%) compared to those expressing EGFP (2.92 ± 1.14%). However, expression of α-synWT-EGFP 269 
(3.19 ± 1.3%) or α-synA53T-EGFP (6.11 ± 2.49%) did not result in a significant proportion of cells 270 
containing inclusions (Figure 1). Moreover, treatment of cells expressing the α-syn-EGFP variants 271 
with proteostasis inhibitors had no significant effect on the percentage of cells containing inclusions, 272 
such that the proportion of cells expressing α-syn with inclusions remained very low (<10%).  273 
To determine whether the lack of aggregation of α-syn into inclusions was due to the cell line being 274 
used (i.e. N2a cells), this experiment was repeated using HEK293 cells (Figure 1C). As expected, 275 
treatment of HEK293 cells expressing TDP-43-tGFP with MG132 and thapsigargin significantly 276 
(p<0.001) increased the proportion of cells with inclusions (36.1 ± 8.56%) compared to cells 277 
expressing EGFP alone (5.40 ± 2.45%). However, as seen for N2a cells, there was no significant 278 
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difference in the percentage of α-syn-EGFP expressing HEK293 cells containing fluorescent inclusions 279 
following treatment with MG132, thapsigargin or FeCl2 compared to cells expressing EGFP alone. In 280 
all cases the percentage of transfected cells expressing α-syn-EGFP with inclusions remained very 281 
low (<7%). As such, it was concluded that EGFP-tagged α-syn variants do not readily aggregate in 282 
cells, and therefore an alternate model was pursued. 283 
α-Syn-A53T* readily aggregates to form inclusions in cells 284 
Previous work attempting to develop a cell model of α-syn aggregation, in which a fluorescently 285 
tagged form of α-syn was expressed in human H4 neuroglioma cells, led to the discovery of 286 
intracellular puncta which were non-fluorescent but immunoreactive to α-syn (McLean et al. 2001). 287 
This work identified a cleavage product of the expressed α-syn-EGFP in these inclusions. This product 288 
consisted of α-syn with a C-terminal fragment of EGFP in which the last 155 residues of EGFP has 289 
been cleaved from the protein. According to the sequences provided for these cleavage products, a 290 
construct was designed for the expression of α-syn fused to a fragment of EGFP (designated α-291 
synA53T*). The propensity of the resulting α-synA53T* to form intracellular inclusions was then 292 
investigated in N2a cells. Following transfection, cells were immunostained for α-syn and mounted 293 
on glass slides for imaging via confocal microscopy (Figure 2A-D). Qualitative analysis of cells positive 294 
for α-syn revealed the formation of fluorescent inclusions in some cells, which appeared to be 295 
distributed throughout the cytosol (Figure 2B, D) and at the periphery of cells (Figure 2C, D). The 296 
presence of these inclusions in transfected cells was quantified, and the percentage of transfected 297 
cells containing inclusions found to be 31 ± 5.5% of the population. Following treatment with the 298 
proteostasis inhibitors 3-MA (autophagy inhibitor) or MG132 (proteasome inhibitor), there was a 299 
significant increase in the percentage of cells containing inclusions compared to the untreated or 300 
DMSO-vehicle treated samples (p<0.05; Figure 2E).  301 
In order to confirm the immunoreactive inclusions represent aggregated α-syn, lysates from cells 302 
transfected to express α-synA53T* (or an EGFP control) were subjected to filter trap analysis. Filter 303 
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trap assays have been used extensively in the past to assess inclusion formation in cells (Chang and 304 
Kuret 2008, Juenemann et al. 2015, Nasir et al. 2015). Typically, soluble protein moves through the 305 
membrane pores, while aggregated protein is retained on the membrane such that proteins in the 306 
aggregates can be detected by immunoblotting. We first established the specificity of this assay for 307 
aggregated α-syn. When recombinant monomeric α-syn was added into buffer at concentrations 308 
that exceed the level of α-synA53T* expressed in cells (see Supplementary Figure 2), it was not 309 
trapped by the filter and therefore was not detected by immunoblotting (Figure 2F). Moreover, no 310 
signal was detected when recombinant monomeric α-syn was added to the lysate from 311 
untransfected cells, thus demonstrating that monomeric α-syn does not aggregate in the cell lysate 312 
as a result of the lysis procedure. Importantly, when recombinant fibrillar α-syn was spiked into 313 
buffer or the lysate from untransfected cells it was trapped by the filter and detected when present 314 
at levels as low as 0.04 µM (Figure 2F). As expected, no α-syn signal was detected in lysates from 315 
mock transfected or EGFP transfected cells (Figure 2G). However, α-syn was detected in cells 316 
transfected to express α-synA53T*, confirming that these cells contained aggregated forms of α-syn. 317 
Moreover, there was a significant increase in the amount of aggregated α-syn detected in lysates 318 
from cells following treatment with the proteostasis inhibitors, thus correlating with the increase in 319 
the number of cells with inclusions following this treatment (Figure 2E). Given the formation of α-syn 320 
immunoreactive fluorescent inclusions corresponded to the accumulation of aggregated α-syn, and 321 
that this accumulation was sensitive to treatment with inhibitors of proteostasis, it was concluded 322 
that expression of α-synA53T* in N2a cells is a suitable cell-based model of α-syn aggregation.  323 
Bicistronic IRES constructs enable sHsp-expressing cells to be identified via an EGFP reporter 324 
First, in order to validate the use of the IRES constructs, the over-expression of the sHsps and EGFP 325 
reporter was confirmed (Figure 3). N2a cells were transiently transfected with constructs expressing 326 
EGFP/αB-c or EGFP/Hsp27. Following incubation for 24 h, cells were probed for sHsp expression with 327 
polyclonal primary and fluorescently-conjugated secondary antibodies before being imaged via 328 
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confocal microscopy. As expected, mock transfected N2a cells were not immunoreactive, indicating 329 
N2a cells do not constitutively express αB-c or Hsp27 (Figure 3A, C). Transfection with the IRES 330 
constructs successfully induced expression of EGFP (Figure 3B, D). When probed with sHsp-specific 331 
antibodies, EGFP-positive cells were also immunoreactive for αB-c or Hsp27 respectively (Figure 3B, 332 
D). Furthermore, this analysis confirms the production of two discrete proteins from the construct, 333 
as the EGFP fluorescence was found to be diffuse throughout the nucleus and cytoplasm, whilst the 334 
sHsps were only localised to the cytoplasm. Overall these data confirm that transfection of N2a cells 335 
with IRES constructs results in the overexpression of the sHsp of interest, and sHsp-expressing cells 336 
can be identified via the EGFP reporter. 337 
sHsps inhibit the deposition of α-synA53T* into inclusions in cells  338 
Having developed a cellular model of α-syn aggregation, this model was then used to examine the 339 
ability of αB-c and Hsp27 to prevent α-syn aggregation in cells. N2a cells were co-transfected with 340 
the α-synA53T* and IRES constructs encoding EGFP and either αB-c, Hsp27 or EGFPinv, and incubated 341 
in the absence or presence of proteostasis inhibitors. Cells were imaged via confocal microscopy, 342 
and those containing αB-c or Hsp27 (or the EGFPinv control) were identified through expression of 343 
the fluorescent reporter EGFP (Figure 4A, green). Cells expressing α-synA53T* were identified by 344 
immunolabelling of the α-synA53T* with DyLight-650 (Figure 4B, red). This allows identification of 345 
cells containing only α-syn (red only), those containing only αB-c or Hsp27 (or the EGFPinv control; 346 
green only), and cells of interest (i.e. co-transfected cells that contain both the α-syn and chaperone 347 
or control protein, yellow) (Figure 4C). The number of cells containing inclusions was then manually 348 
quantified using randomly imaged fields of view and the percentage of co-transfected cells 349 
containing inclusions was then calculated and normalised to the EGFP control (Figure 4D). Expression 350 
of αB-c was found to significantly reduce the number of cells containing inclusions in untreated cells 351 
(p<0.05) and in those treated with the proteostasis disruptors thapsigargin and MG132 (p<0.01) 352 
(Figure 4D). Whilst αB-c also reduced the proportion of cells containing inclusions following 353 
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treatment with 3-MA, this effect was not found to be significant.  Co-transfection with Hsp27 was 354 
found to significantly reduce inclusion formation in both the untreated and treated cells expressing 355 
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Discussion 358 
The potent anti-aggregation properties of the sHsps, αB-c and Hsp27, have been well established in 359 
vitro (Bruinsma et al. 2011, Cox et al. 2016). However, in order to capture the complex factors 360 
influencing protein aggregation in the cell, it is essential to complement these in vitro studies with 361 
cellular models of aggregation. Here we have developed a cell-based model of α-syn aggregation in 362 
which α-syn readily aggregates to form inclusions in a significant proportion of transfected cells. We 363 
then used this cell-based model to assess the ability of αB-c and Hsp27 to prevent α-syn aggregation 364 
in cells. Our work shows that expression of αB-c or Hsp27 significantly decreased the proportion of 365 
cells containing α-syn inclusions, even when the cells were treated with inhibitors of autophagy or 366 
the proteasome. These data provide strong evidence that the sHsps are potent inhibitors of α-syn 367 
aggregation in cells.  368 
Fusion of a fluorescent protein to a protein of interest is a well described method for studying 369 
intracellular aggregation and a key element in facilitating high throughput analyses (Ramdzan et al. 370 
2012). Thus, the first approach to study the effect of sHsps on intracellular α-syn aggregation 371 
investigated in this work was to tag the α-syn variants with a C-terminal EGFP. Whilst some cells 372 
expressing α-syn-EGFP were found to contain aggregates, the proportion of these cells was very low 373 
(5 – 10% of cells) and did not increase even in the presence of proteostasis inhibitors or inducers of 374 
cell stress, both of which have been previously reported to increase α-syn aggregation in cells 375 
(Bertoncini et al. 2007). Thus, it is concluded that the addition of this relatively large (approximately 376 
27 kDa) fluorescent protein to the C-terminus of α-syn (14.5 kDa) likely interferes with the physical 377 
properties of α-syn, significantly altering the structure, conformation and/or chemical properties of 378 
the protein, such that its propensity to aggregate in cells is low (Crivat and Taraska 2012). In 379 
addition, previous studies have demonstrated that expression of α-syn alone (i.e. without a tag) 380 
does not result in significant levels of aggregation in cells (Paxinou et al. 2001, Matsuzaki et al. 2004).  381 
However, a cellular cleavage product of α-syn-EGFP, in which the last 155 residues of EGFP have 382 
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been removed, was found to readily aggregate into inclusions in cells (McLean et al. 2001). In this 383 
work we also report that this α-synA53T* protein readily forms inclusions in cells, which are 384 
detectable via immunolabelling of α-syn and by filter-trap assay. Notably, a significant proportion of 385 
cells transfected to express α-synA53T* developed inclusions (~30%) and this could be significantly 386 
increased by treatment of the cells with inhibitors of proteostasis pathways (i.e. the proteasome and 387 
autophagy). Moreover, it has been previously demonstrated that the aggregation of α-synA53T* into 388 
inclusions is mediated by the α-syn portion of the protein, since when the same fragment of EGFP 389 
was fused to other proteins (i.e. tubulin and synaptophysin) and expressed in cells, these cells did 390 
not develop aggregates (McLean et al. 2001). Thus, it is likely that the additional EGFP fragment at 391 
the C-terminus of α-syn acts to destabilise α-syn and that this is key to recapitulating the cellular 392 
aggregation of α-syn associated with disease.  393 
Importantly, C-terminal cleavage products of α-syn (α-synΔC) have been identified in vivo. For 394 
example, human brain extracts containing pathological α-syn Lewy bodies have significant levels of 395 
α-synΔC, which preferentially localises to detergent-insoluble fractions following extraction of 396 
protein aggregates (Li et al. 2005). Moreover, C-terminal truncation of α-syn significantly increases 397 
its aggregation propensity when compared to full length α-syn when assessed using in vitro ThT-398 
based aggregation assays (Hoyer et al. 2004, Li et al. 2005). In addition, the incorporation of 399 
substoichiometric ratios of α-synΔC variants significantly enhances the aggregation of cellular 400 
aggregation of full length α-syn (Li et al. 2005). Finally, α-synΔC variants increase the vulnerability of 401 
cells in culture to toxic assault by oxidative stressors (Kanda et al. 2000). Together, these data 402 
indicate that the C-terminal region of α-syn plays a critical role in governing its propensity to 403 
aggregate. Thus, this may account, at least in part, for the increased propensity of α-synA53T* to 404 
form inclusions in cells. A cell model that incorporates co-expression of full-length α-syn with an α-405 
synΔC isoform may also result in a robust cellular model of α-syn aggregation.  406 
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Whilst this work demonstrated that αB-c and Hsp27 can prevent a-syn aggregation in cells, the 407 
molecular mechanism(s) by which this occurs remains to be established. These sHsps may interact 408 
with monomeric aggregation-prone α-syn to prevent the formation of oligomeric nuclei, as has been 409 
observed in solution-based experiments [17]. Alternatively, sHsps may bind to small α-syn oligomers 410 
and, in doing so, prevent growth of these oligomers into fibrillar species that would otherwise lead 411 
to their deposition into inclusions. sHsps may also interact with fibrillar α-syn in order to prevent 412 
secondary nucleation processes that would otherwise increase the amount of aggregated material 413 
and enhance deposition of α-syn into inclusions. It is most likely that the inhibition of α-syn inclusion 414 
formation by αB-c and Hsp27 is due to a combination of these mechanisms. Importantly, even in the 415 
presence of proteostasis inhibitors, the sHsps successfully inhibited the formation of α-syn 416 
inclusions. This suggests that the sHsp mechanism of action is independent of these protein 417 
degraadation pathways, and implies that the sHsps most likely inhibit inclusion formation by 418 
preventing the initial aggregation of α-syn, rather than promoting its degradation via the ubiquitin-419 
proteasome system or autophagy. Development of techniques that enable the aggregation state of 420 
α-syn to be tracked in cells so that this can be linked to specific biological outcomes would greatly 421 
assist future work in this area. For example, the development of conformational sensors of α-syn 422 
capable of distinguishing monomeric, oligomeric and fibrillar species, such as those developed for 423 
Htt (Ormsby et al. 2013), would facilitate investigation of the precise mechanism(s) by which sHsps 424 
act to prevent α-syn aggregation in cells.  425 
An important aspect of this work was the use of biscistronic vectors for the expression of the sHsps 426 
(and an ‘invisible’, non-fluorescent variant of EGFP, EGFPinv as a control). These constructs enabled 427 
the chaperone activity of the sHsps to be evaluated without the confounding effects of associated 428 
with tagging them with a bulky fluorescent protein. Traditional fluorescent fusion approaches to 429 
monitor chaperones in cells have been shown to impact the ability of sHsps to form oligomeric 430 
assemblies and undergo subunit exchange, processes which are crucial for chaperone efficacy 431 
(Datskevich et al. 2012a, Datskevich et al. 2012b, Datskevich and Gusev 2014). However, the 432 
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bicistronic expression system provides a method to distinguish cells containing the chaperone of 433 
interest without adversely affecting the oligomeric and dynamic nature of these proteins. These 434 
bicistronic constructs are therefore advantageous for studying sHsp function in cells. This approach 435 
could also be used to study other proteins in cells whose structure and/or function may be adversely 436 
affected by the addition of a fluorescent protein tag. 437 
In summary, in this work we report on a cell-based model of α-syn aggregation and, using this 438 
model, demonstrate that the sHsps, Hsp27 and αB-c, prevent the aggregation of α-syn into 439 
inclusions in cells. By exploiting a bicistronic vector, sHsp expression and function was able to be 440 
assessed in individual cells without the need for a fluorescent tag, which can otherwise compromise 441 
the structure and activity of these oligomeric and dynamic chaperone proteins. This work indicates 442 
that the sHsps are valid therapeutic targets for aggregation-based diseases such as the α-443 
synucleinopathies.  444 
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Figure Legends 579 
Figure 1: Expression of fluorescently tagged α-syn isoforms does not result in a substantial number 580 
of N2a or HEK293 cells with inclusions. N2a or HEK293 cells were transiently transfected with 581 
constructs encoding for EGFP (negative control), TDP-43-tGFP (positive control) or EGFP-tagged 582 
variants of α-synWT or α-synA53T. Cells were treated with proteostasis inhibitors (10 µM MG132, 3 583 
μM thapsigargin, or 10 mM FeCl2) as indicated and incubated for 48 h before being mounted on 584 
glass slides and imaged via confocal microscopy. Images were randomly collected according to the 585 
brightfield channel, and the number of EGFP-positive cells containing diffuse or aggregated 586 
fluorescent protein was manually quantified using (A, right panel) an overlay of the brightfield and 587 
fluorescent images. Examples of cells counted as (1) diffuse fluorescence and (2) punctate 588 
fluorescence are shown. Scale bars represent 25 μm, and 5 µm in inset. The percentage of EGFP-589 
positive cells containing inclusions for (B) N2a or (C) HEK293 cells following each treatment is 590 
displayed as mean ± S.E.M. (n=3), and was analysed via a one-way ANOVA with a Dunnett’s post-test 591 
compared to the untreated EGFP control, where *** indicates p<0.001. 592 
 593 
Figure 2: α-synA53T* forms punctate inclusions in N2a cells.  N2a cells were transiently transfected 594 
with a construct expressing α-synA53T* and incubated for 48 hours before being treated (or not) 595 
with 3-MA (10 mM), MG132 (10 µM) or an equivalent volume of the vehicle control (DMSO) and 596 
incubated for a further 48 hours. Intracellular α-syn was fluorescently labelled via 597 
immunohistochemistry, using a monoclonal mouse anti-αsyn antibody and a DyLight650-conjugated 598 
anti-mouse secondary antibody. (A-D) Fluorescent images of cells containing both cytosolic 599 
intracellular (A, B) and membrane-localised (C, D) inclusions are presented. Scale bars represent 5 600 
µm. (E) The percentage of cells containing inclusions was quantified by manually counting at least 50 601 
transfected cells and the number of α-syn positive cells containing fluorescent inclusions 602 
enumerated. Data are displayed as mean ± S.E.M. (n=4), and was analysed via one-way ANOVA with 603 
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a Dunnett’s multiple comparison post-test, where * indicates p<0.05 compared to untreated or 604 
DMSO-treated controls. (F) Monomeric or fibrillar recombinant α-syn was added at various 605 
concentrations (0 – 0.5 µM) to either 50 mM phosphate buffer (pH 7.4) or 200 µg of untransfected 606 
cell lysate. Samples were analysed via filter trap using a 0.2 µm membrane, and detected using a 607 
monoclonal mouse anti-α-syn followed by a HRP-conjugated secondary antibody. (G) Cell extracts 608 
prepared from (i) mock transfected cells, and cells transfected with (ii) an EGFP vector control or (iii) 609 
the α-synA53T* construct. Cells were incubated in the absence (Untreated) or presence (Treated) of 610 
proteostasis inhibitors (10 µM MG132 and 3 µM thapsigargin). Samples were analysed via filter trap 611 
using a 0.2 µm membrane, and detected using a monoclonal mouse anti-α-syn followed by a HRP-612 
conjugated secondary antibody. Samples in F and G were analysed on the one membrane, and the 613 
image from this membrane has been truncated for clarity. 614 
 615 
Figure 3: sHsps are overexpressed following transfection with IRES bicistronic constructs. N2a cells 616 
were mock transfected (A, C), or transiently transfected with IRES constructs expressing (B) 617 
EGFP/αB-c or (D) EGFP/Hsp27. Forty-eight hours following transfection, cells were immunolabelled 618 
for intracellular sHsps using polyclonal rabbit anti-sHsp antibodies. Transfected cells were identified 619 
via EGFP fluorescence, and sHsps were visualised using DyLight650-conjugated secondary 620 
antibodies. Scale bars represent 25µm. 621 
 622 
Figure 4: sHsps inhibit the formation of α-syn inclusions in cells.  N2a cells were transiently 623 
transfected with a construct expressing α-synA53T*, along with an IRES construct expressing 624 
EGFP/αB-c, EGFP/Hsp27 or EGFP/EGFPinv. Forty-eight hours following transfection, cells were treated 625 
with MG132 and thapsigargin (10 µM and 3 µM, respectively) or 3-MA (10 mM), then incubated for 626 
a further 48 h. Intracellular α-syn was immunohistochemically labelled, using a monoclonal mouse 627 
anti-αsyn antibody and a DyLight650-conjugated secondary antibody. (A) Cells containing αB-c 628 
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display EGFP fluorescence, and (B) α-syn positive cells display red fluorescence. (C) Fluorescence 629 
images overlayed on the brightfield channel allow automated detection and selection of co-630 
transfected cells. (D) The percentage of co-transfected cells containing inclusions was quantified by 631 
manually selecting cells positive for α-syn expression and containing inclusions, and then removing 632 
cells that were not co-transfected. Data is displayed as mean ± S.E.M. (n=3 biological repeats, each 633 
consisting of at least 50 cells), and was analysed via two-way ANOVA with a Bonferroni post-test, 634 
where * indicates p<0.05 and ** indicates p<0.01 within treatment groups when compared to the 635 
EGFPinv control. 636 
 637 
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